← 返回前沿论文

细胞免疫治疗用于胰腺癌的进展与前景

英文原题:Progress and prospects for use of cellular immunotherapy in pancreatic cancer.

查看英文原题

Progress and prospects for use of cellular immunotherapy in pancreatic cancer.

PubMed 2022/12/01(内容时间) J Cancer Res Ther Q4 · IF 1.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺癌(PC)是一种高度恶性的肿瘤,近年来发病率不断上升。由于其起病隐匿、病理生理机制不明且预后较差,即便采用手术、放疗、生物治疗和靶向治疗等多种方法,患者总生存率仍未明显改善。因此,开发更安全、有效的胰腺癌治疗方法至关重要。近年来,细胞免疫疗法在肿瘤学领域取得显著进展,技术不断发展,几乎每月都有新突破,胰腺癌治疗效果有望进一步改善。本文探讨嵌合抗原受体NK 细胞(CAR-NK)免疫疗法在胰腺癌研究中的进展,并介绍胰腺癌治疗的研究思路。

展开英文摘要原文

Pancreatic cancer (PC) is a highly malignant tumor with an increasing incidence rate in recent years. Because pancreatic cancer has an insidious onset, unknown pathophysiology, and poor prognosis, the overall survival rate of pancreatic cancer patients has not improved considerably even with extensive treatment methods such as surgery, radiation, biotherapy, and targeted therapy.

Therefore, finding and developing more effective and safe treatments for pancreatic cancer is critical. Cellular immunotherapy has achieved considerable advances in the field of oncology in recent years.

Technology is continuously advancing, with new breakthroughs virtually every month, and pancreatic cancer eradication is expected to improve considerably. This article examines the advance of chimeric antigen receptor NK cell immunotherapy (CAR-NK) cell immunotherapy for pancreatic cancer research, as well as research ideas for pancreatic cancer treatment.

论文信息

作者
Tian J、Bai T、Zhang Z、Zhai X、Wang K、Gao X、Yan B
单位
School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.China
文献类型
综述
期刊
Journal of cancer research and therapeutics2022 Dec
原文标识
PubMed 36647944 · DOI 10.4103/jcrt.jcrt_976_21